CoChat

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

Open access
Richardson, Paul G., Badros, Ashraf Z., Jagannath, Sundar, Tarantolo, Stefano, Wolf, Jeffrey L., Albitar, Maher, Berman, David, Messina, Marianne, Anderson, Kenneth C. · 2010 · British Journal of Haematology
Cited by 77

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary: Tanespimycin (17‐allylamino‐17‐demethoxygeldanamycin, 17‐AAG) disrupts heat shock protein 90 (HSP90), a key molecular chaperone for signal transduction proteins critical to myeloma growth, survival and drug resistance. In previous studies, tanespimycin monotherapy was well tolerated and active in heavily pretreated patients with relapsed/refractory multiple myeloma (MM). Preclinical data have shown antitumour synergy between tanespimycin and bortezomib, with more pronounced intracellular accumulation of ubiquitinated proteins than either drug alone, an effect attributed to the synergistic suppression of chymotryptic activity in the 20S proteasome. HSP70 induction has been observed in all Phase 1 tanespimycin studies in which it has been measured, with several separate reports of HSP70 overexpression protecting against peripheral nerve injury. In this Phase 2, open‐label multicentre study, we compared 1·3 mg/m 2 bortezomib + three doses of tanespimycin: 50, 175 and 340 mg/m 2 in heavily pretreated patients with relapsed and refractory MM and measured HSP70 expression and proteasome activity levels in plasma of treated patients. The study was closed prematurely for resource‐based reasons, precluding dose comparison. Nonetheless, antitumour activity was observed, with promising response rates and promising severity of peripheral neuropathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2010.08264.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 77

Metadata

Authors
Richardson, P. G., Badros, A. Z., Jagannath, S., Tarantolo, S., Wolf, J. L., Albitar, M., Berman, D., Messina, M., & Anderson, K. C.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2010-08
Volume
150
Issue
4
Pages
428-437
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1552240270
Cited by
77
References
3
FWCI
6.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08264.x
The paper
Richardson, P. G., Badros, A. Z., Jagannath, S., Tarantolo, S., Wolf, J. L., Albitar, M., Berman, D., Messina, M., & Anderson, K. C. (2010). Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08264.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.